Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: siogtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2022 | $10.00 → $7.00 | Buy | HC Wainwright & Co. |
| 2/1/2022 | $6.00 → $1.00 | Outperform → Market Perform | SVB Leerink |
| 10/21/2021 | $8.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/12/2021 | $7.00 → $6.00 | Outperform | SVB Leerink |
| 7/12/2021 | $12.50 | Buy | Chardan Capital Markets |